
ð§¬ç¬¬38åïœéºäŒå補å€ã®ãªã¹ã¯ãã¥ãŒã¹ã5幎ç®ã®çå®ãmRNAã¯ã¯ãã³ã500äžä»¶ãã®çäŸããæŽãæ°ããªãªã¹ã¯ãšã¯âïž
ä»åã®èšäºã§ã¯ã2026幎6æã«çºè¡šãããmRNAã¯ã¯ãã³ã®å®å šæ§ã«é¢ããææ°ã®è«æã«ã€ããŠè§£èª¬ããŸã ãïŒè«ææ å ±ã¯èšäºæ«å°ŸãžïŒ
çãåç»ã«ããã®ã§ããŸãã¯ãµã¯ããšã芧ããã ããã°ãšæããŸãã
ð èŠç¹

äžçäžã®èšå€§ãªããŒã¿ãåæïŒ5幎éã«éãŸã£ãçŽ504äžä»¶ã®å¯åå¿å ±åãšãçŽ4,300ä»¶ã®å»åŠè«æãããŸãªã調ã¹ãŸãã ã
æ°ããæ³šæãã¹ãçç¶ïŒã·ã°ãã«ïŒã®çºèŠïŒãããŸã§ã®èª¬ææžã«ã¯èŒã£ãŠããªãã£ããè¡æ¶²ã®ç æ°ãè³ã®ç æ°ïŒé£èŽãªã©ïŒãªã©ã®çç¶ãæ°ããæ€åºãããŸãã ã
å¿ççã»å¿èçã®ã¡ããïŒå¿èã®ççã¯è¥ãç·æ§ã«å€ãèµ·ããŠããŸããããåœã«é¢ããéãã±ãŒã¹ã¯é«éœ¢è ã«éäžããŠããŸãã ã
ç¹ã«æ³šæãå¿ èŠãªäººïŒã幎å¯ãããããšããšæç ããã人ã¯ãéãå¯åå¿ãåºããªã¹ã¯ãé«ãããšãåãããŸãã ã
ð ã©ããªç ç©¶ïŒ


ä»åã®ç ç©¶ã¯ãmRNAã¯ã¯ãã³ã䜿ããå§ããŠããã®5幎éã®ãªã¢ã«ãªããŒã¿ïŒçŸå®äžçããŒã¿ïŒãçµ±åãããã®ã§ã ã
ç ç©¶ããŒã ã¯ã以äžã®2ã€ã®ããŒã¿ã䜿ã£ãŠåæãè¡ããŸããã
VAERSïŒç±³åœã®å¯åå¿å ±åã·ã¹ãã ïŒïŒçŽ504äžä»¶
ALDïŒäžçã®å»åŠè«æããŒã¿ããŒã¹ïŒïŒ4,387ä»¶
ããããçµ±èšã®æè¡ã䜿ã£ãŠåæããã¯ã¯ãã³ãšå¯åå¿ã®éã«ã©ã®ãããªé¢ä¿ããããã調ã¹ãŸãã ã
ðš åãã£ãããšâ ïŒæ°ããæ€åºãããçç¶ïŒã·ã°ãã«ïŒ


åæã®çµæãã¯ã¯ãã³ã®èª¬ææžïŒæ·»ä»ææžïŒã«ã¯ãŸã ã¯ã£ãããšæžãããŠããªããæ°ããçç¶ã®ã·ã°ãã«ãããã€ãèŠã€ãããŸãã ã
ð©ž è¡æ¶²ããªã³ãã®ç æ°
è¡æ æ§è¡å°æ¿æžå°æ§çŽ«æç ïŒTTPïŒïŒè¡æ ïŒè¡ã®å¡ïŒãã§ããŠããŸããåºè¡ãããããªãé倧ãªç æ°ã§ã ãã³ãããã£ïŒãã¡ã€ã¶ãŒè£œïŒãšã¹ãã€ã¯ããã¯ã¹ïŒã¢ãã«ã補ïŒã®äž¡æ¹ã§ã·ã°ãã«ãèŠã€ãããŸãã ã
ð è³ã®ç æ°
é£èŽãçªç¶ã®å€±èŽïŒè³ãèããã«ãããªã£ãããçªç¶èãããªããªã£ããããçç¶ã§ã ãäž»ã«ã³ãããã£ã§ã·ã°ãã«ã確èªãããŸãã ã
ðº æçµïŒççïŒã®ä¹±ã
æçµçïŒçççïŒã®æªåããäºå®æ¥ã®é ãïŒã¯ã¯ãã³ã®åœ±é¿ã§å ç«ãççåå¿ãå€åããããšãåå ã§ã¯ãªãããšæšæž¬ãããŠããŸã ã
ð¡ã泚æã ãããã®çç¶ãåºããããšãã£ãŠãã100%ã¯ã¯ãã³ã®ããããšæå®ãããããã§ã¯ãããŸãã ãããããçµ±èšçã«ç¡èŠã§ããªãåæ°ã®å ±åãéãŸã£ãŠããããããããããã£ãšæ³šææ·±ãç£èŠããŠããå¿ èŠããããŸã ã
ð« åãã£ãããšâ¡ïŒå¿ççãšå¿èçã®ãªã¢ã«ãªããŒã¿
ã¯ã¯ãã³ã®å¯åå¿ãšããŠç¥ãããŠããå¿ççïŒå¿èã®çèã®ççïŒãšå¿èçïŒå¿èãå ãèã®ççïŒã«ã€ããŠãå¹Žéœ¢ãæ§å¥ã«ããã¯ã£ãããšããç¹åŸŽãåãããŸãã ã


èµ·ãããã人ïŒ18æ³ã44æ³ã®è¥ãç·æ§ã«å€ãå ±åãããŠããŸã ãç·æ§ã®æ¹ã女æ§ãããäœã幎霢ã§èµ·ããåŸåããããŸã ã
éçåãããã人ïŒå¿ççãªã©ãåå ã§äº¡ããªã£ãŠããŸãã±ãŒã¹ã¯ãè¥ã人ã§ã¯ãªã65æ³ä»¥äžã®é«éœ¢è ã«å€ãã¿ãããŸãã ã
ç·æ§ã«å€ãã¿ãããçç±ãšããŠãç·æ§ãã«ã¢ã³ã女æ§ãã«ã¢ã³ã®ã¡ãããªã©ãäœã®ä»çµã¿ïŒçç©åŠçã¡ã«ããºã ïŒãé¢ä¿ããŠãããšèããããŠããŸãã
â ïž åãã£ãããšâ¢ïŒã©ããªäººãéãçç¶ã«ãªããããïŒ
å¯åå¿ã®äžã§ããå ¥é¢ãå¿ èŠã«ãªã£ããåœã«é¢ãã£ããããé節ãªå¯åå¿ïŒSAEïŒã«ã€ããŠèª¿ã¹ãçµæã§ã ã



å¹Žéœ¢ãšæç ïŒå¹Žéœ¢ãé«ã人ããããšããšäœã«æç ïŒå»çæŽïŒããã人ã»ã©ãéãå¯åå¿ã«ãªããªã¹ã¯ãé«ãããšãåãããŸãã ã
æ§å¥ã®ã¡ããïŒå šäœã®å ±åæ°ãšããŠã¯å¥³æ§ã®æ¹ãå€ãã§ãããæ»äº¡ããŠããŸãã±ãŒã¹ã¯ç·æ§ã®æ¹ãé«ããšããçµæãåºãŠããŸã ã
åæ°ã«ããã¡ããïŒå šäœã®æ°ãšããŠã¯1åç®ã®æ¥çš®ïŒååå ç«ïŒã§å€ãå ±åãããŸããã2åç®ä»¥éã®è¿œå æ¥çš®ïŒããŒã¹ã¿ãŒïŒã®æ¹ããéãçç¶ãåºãå²åãé«ããªãåŸåãã¿ãããŸãã ã
ð¢ ãŸãšã

ä»åã®5幎éã«ãããäžççãªèª¿æ»ãããmRNAã¯ã¯ãã³ã«ã¯ãŸã ç§ãã¡ãæ éã«èŠå®ã£ãŠããã¹ãçç¶ããç¹ã«æ³šæãã¹ã人ã ïŒé«éœ¢è ãæç ã®ããæ¹ïŒãããããšãã¯ã£ãããšåãããŸãã ã
ç ç©¶ããŒã ã¯ããããããã¯ãã幎å¯ããæç ã®ãã人ãããæ³šææ·±ãèŠå®ããäžäººã²ãšãã«åãããå®å¿ã»å®å šãªæ¥çš®æŠç¥ãèããŠããå¿ èŠãããããšçµè«ã¥ããŠããŸã ã
ð 玹ä»è«æ
Tulisibaike, B., Yang, T.-Y., Gu, W.-J., et al. (2026). "Post-Marketing Safety of mRNA Vaccines: A Real-World Study Integrating Literature Case Reports and Vaccine Adverse Event Reporting System." Vaccines, 14(6), 524.
ïŒmRNAã¯ã¯ãã³ã®è£œé 販売åŸå®å
šæ§ïŒæç®çäŸå ±åãšã¯ã¯ãã³å¯åå¿å ±åã·ã¹ãã ãçµ±åãããªã¢ã«ã¯ãŒã«ãç ç©¶ïŒ
æ»èªã¹ããŒã¿ã¹ïŒæ¬è«æã¯æ»èªæžã¿ïŒPeer-reviewedïŒã§ã ãå€éšã®å°éå®¶ã«ããå³ãã審æ»ãšæ¹èšããã»ã¹ïŒ2026幎4ææåºã6ææ¹èšã»æ¡æïŒãçµãŠãæ£åŒã«åŠè¡èªã«æ²èŒãããŠããŸã ã
å·çåœã»ç ç©¶æ©é¢ïŒäžåœãšã¢ã¡ãªã«ã®åœéå ±åç ç©¶ã§ã ã
äž»ã«äžåœã®å京å»ç§å€§åŠïŒã¯ã¯ãã³ã€ãããŒã·ã§ã³ãã©ãããã©ãŒã ãå»è¬åç£èŠç ç©¶æãèšåºè¬çåŠéšéãæ±èççŸç äºé²ç®¡çã»ã³ã¿ãŒãªã©ïŒã®ç ç©¶ããŒã ãäžå¿ãšãªã£ãŠããŸã ã
å ±åå·çãšããŠãã¢ã¡ãªã«ã»ãã¥ãŒãšãŒã¯ã®ããŠã³ããµã€ãã€ã»ãŠã§ã¹ãç é¢ã®å€ç§åŠéšéã®ç ç©¶è ãåç»ããŠããŸã ã
URLïŒhttps://www.mdpi.com/2076-393X/14/6/524
é¢é£ããŠã以äžã®åç»ãåãããŠã©ãŒã âºïž
ãè»ãè²·ãæãšåããç®ãŠãã¯ã¯ãã³ãèŠãã
ãããŸã§ã®è§£èª¬åç»ãå šéšèŠããŸãð
åãåãã転çšããèªç±ã«âïž
ãðŽ ãã£ã³ãã«ç»é²ãïŒãð éç¥ONãããŠããã ããšãæ°ããåç»ãå ¬éãããéã«ããèŠããŸãð ã³ã¡ã³ãããèªç±ã«ïŒ
以äž